Table 2.
Characteristics of patients with immediate breast reconstruction after mastectomy for ipsilateral breast cancer local recurrence (n = 68).
| Characteristics | Total IBR (n = 68) | NSM (n = 31, 45.6%) | SSM (n = 37, 54.4%) | p |
|---|---|---|---|---|
| IBR type, n (%) | 0.063 | |||
| Implant | 20 (29.4) | 9 (29.0) | 11 (29.7) | |
| Expander | 11 (16.2) | 1 (3.2) | 10 (27.0) | |
| LDF non autologous | 4 (5.9) | 3 (9.7) | 1 (2.7) | |
| Autologous LDF | 25 (36.8) | 14 (45.2) | 11 (29.7) | |
| LDF non autologous + implant | 4 (5.9) | 3 (9.7) | 1 (2.7) | |
| Autologous LDF + implant | 4 (5.9) | 1 (3.2) | 3 (8.1) | |
| Age, n (%) | 0.153 | |||
| ≤40 | 2 (2.9) | 2 (6.5) | 0 (0) | |
| 41–50 | 12 (17.6) | 6 (19.4) | 6 (16.2) | |
| 51–74 | 47 (69.1) | 22 (71.0) | 25 (67.6) | |
| ≥75 | 7 (10.3) | 1 (3.2) | 6 (16.2) | |
| BMI, n (%) | 0.299 | |||
| <25 | 51 (75.0) | 26 (83.9) | 25 (67.6) | |
| 25–29.9 | 14 (20.6) | 4 (12.9) | 10 (27.0) | |
| ≥30 | 3 (4.4) | 1 (3.2) | 2 (5.4) | |
| Tobacco, n (%) | 0.101 | |||
| No | 54 (79.4) | 22 (71.0) | 32 (86.5) | |
| Yes | 14 (20.6) | 9 (29.0) | 5 (13.5) | |
| Diabetes, n (%) | 0.708 | |||
| No | 66 (97.1) | 30 (96.8) | 36 (97.3) | |
| Yes | 2 (2.9) | 1 (3.2) | 1 (2.7) | |
| ASA, n (%) | 0.131 | |||
| 1 | 20 (29.4) | 11 (35.5) | 9 (24.3) | |
| 2 | 44 (64.7) | 20 (64.5) | 24 (64.9) | |
| 3 | 4 (5.9) | 0 (0) | 4 (10.8) | |
| Cup size, n (%) | 0.734 | |||
| A-B | 36 (52.9) | 18 (58.1) | 18 (48.6) | |
| C | 25 (36.8) | 10 (32.3) | 15 (40.5) | |
| ≥C | 7 (10.3) | 3 (9.7) | 4 (10.8) | |
| Complication | 0.252 | |||
| No | 37 (54.4) | 15 (48.4) | 22 (59.5) | |
| Yes | 31 (45.6) | 16 (51.6) | 15 (40.5) | |
| Reoperation | 0.259 | |||
| No | 60 (88.2) | 26 (83.9) | 34 (91.9) | |
| Yes | 8 (11.8) | 5 (16.1) | 3 (8.1) | |
| Grade complication | 0.717 | |||
| 0 | 37 (54.4) | 15 (48.4) | 22 (59.5) | |
| 1 | 21 (30.9) | 10 (32.3) | 11 (29.7) | |
| 2 | 2 (2.9) | 1 (3.2) | 1 (2.7) | |
| 3 | 8 (11.8) | 5 (16.1) | 3 (8.1) | |
| Grade 2–3, n (%) | 0.258 | |||
| No | 58 (85.3) | 25 (80.6) | 33 (89.2) | |
| Yes | 10 (14.7) | 6 (19.4) | 4 (10.8) | |
| Mastectomy weight, n (%) | 0.131 | |||
| ≤300 g | 40 (58.8) | 21 (67.7) | 19 (51.4) | |
| >300 g | 28 (41.2) | 10 (32.3) | 18 (48.6) | |
| Axillary, n (%) | ||||
| No | 49 (72.1) | 25 (80.6) | 24 (64.9) | |
| SLNB | 16 (23.5) | 5 (16.1) | 11 (29.7) | |
| ALND | 3 (4.4) | 1 (3.2) | 2 (5.4) | |
| Years, n (%) | 0.115 | |||
| 2016 | 20 (29.4) | 5 (16.1) | 15 (40.5) | |
| 2017 | 25 (36.8) | 14 (45.2) | 11 (29.7) | |
| 2018 | 19 (27.9) | 9 (29.0) | 10 (27.0) | |
| 2019 | 4 (5.9) | 3 (9.7) | 1 (2.7) | |
| Chemotherapy, n (%) | 0.270 | |||
| No | 56 (82.4) | 27 (87.1) | 29 (78.4) | |
| Yes | 12 (17.6) | 4 (12.9) | 8 (21.6) | |
| Endocrine therapy, n (%) | 0.176 | |||
| No | 32 (47.1) | 17 (54.8) | 15 (40.5) | |
| Yes | 36 (52.9) | 14 (45.2) | 22 (61.1) | |
| Histologies types, n (%) | 0.023 | |||
| DCIS | 23 (33.8) | 16 (51.6) | 7 (18.9) | |
| NST | 35 (51.5) | 11 (35.5) | 24 (64.9) | |
| Lobular | 7 (10.3) | 2 (6.5) | 5 (13.5) | |
| Others* | 3 (4.4) | 2 (6.5) | 1 (2.7) | |
| POHL, n (%) | 0.412 | |||
| ≤3 | 35 (51.5) | 15 (48.4) | 20 (54.1) | |
| >3 | 33 (48.5) | 16 (51.6) | 17 (45.9) |
ALND, axillary lymph node dissection; BMI, body mass index; DCIS, ductal carcinoma in situ; IBR, immediate breast reconstruction; LDF, latissimus dorsi-muscle flap; Others*, tubular, mucinous, medullary breast carcinoma. POHL, post-operative hospitalization lengths; NST, nonspecific tumor; NSM, nipple sparing mastectomy, % percentage; SLNB, sentinel lymph node biopsy; SSM skin sparing mastectomy; Autologous LDF, Latissimus dorsi-muscle with fat around muscle.